ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1571

Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort

Guy Katz1, sandeep hedgire1, James Stone2, Sebastian Perez-Espina1, Ana Fernandes1, Cory Perugino1, Zachary Wallace1 and John Stone3, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Reading, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Heart disease, IgG4 Related Disease, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic autoimmune fibroinflammatory disease capable of affecting most organ systems. Large-vessel vasculitis is a well-described manifestation of the disease. However, coronary artery involvement, while rarely reported, is not well described. We aimed to characterize coronary involvement in 13 patients with IgG4-RD, the largest single-center experience with this manifestation reported to date.

Methods: Patients with coronary involvement of IgG4-RD were identified from our IgG4-RD cohort (n=359). Cases were defined as having coronary involvement if there was wall thickening or enhancement, periarterial soft tissue encasement, or aneurysm involving a coronary artery. Cases with only calcification or luminal stenosis but no other abnormalities were not considered to have coronary involvement. We extracted details regarding patients’ diagnoses and characteristics of coronary involvement through manual chart review.

Results: Thirteen patients had IgG4-RD with coronary involvement. All were male, and median age at diagnosis of coronary involvement was 61 years (range 46-75, IQR 55-69) years. Timing of symptom onset could not be determined in 3 patients; in the remaining 10, median disease duration at diagnosis of coronary involvement was 11 years (IQR 8.3-15.5). Coronary involvement was identified incidentally (2/13), during workup or monitoring of IgG4-RD (7/13), or during workup of cardiac symptomatology (4/13). All patients had elevated serum IgG4 concentrations (median 955.4 [510-1568.3] mg/dL, range 235.2-1980, normal < 86.4 mg/dL), and they had a mean of 4.8 (1.9) organs involved. Concurrent large-vessel involvement was observed in 9/13 cases. Representative histology from a carotid artery is shown in Figure 1. Coronary artery aneurysms were present in 8/13, and these often met criteria for “giant” aneurysms. The largest measured 5.0 cm in diameter. Other abnormalities were periarterial soft tissue encasement (6/13), wall thickening or enhancement (8/13), calcification (9/13), and stenosis (9/13) (Figure 2). Advanced imaging demonstrated that both arteritis and periarteritis could occur (Figure 3). Complications included myocardial infarction (5/13), mural thrombus (5/13), and ischemic cardiomyopathy (2/13); percutaneous coronary intervention and coronary artery bypass grafting were performed in 2 patients each.

Conclusion: Coronary arteritis and periarteritis are manifestations of IgG4-RD, particularly in males with highly-elevated serum IgG4 concentrations and multiorgan disease. Patients are also likely asymptomatic for years, yet severe complications can occur. Our cohort likely underestimates the prevalence of coronary involvement, as patients did not routinely undergo coronary imaging.

Supporting image 1

Figure 1. Histopathology. Carotid artery biopsy at A) 20x magnification and B) 400x magnification showing dense lymphoplasmacytic infiltrate with >200 IgG4+ cells/high-powered field. C) CD138 stain and D) IgG4 stain demonstrate that 56% of CD138+ cells are IgG4+.

Supporting image 2

Figure 2. Major patterns of coronary artery involvement in IgG4-related disease. Images include axial CT (A), left heart catheterization (B), 3D volume-gated reconstruction of CTA (C), and curved planar reformatting of coronary CTA (D-G). Findings include fusiform aneurysmal dilatation (A-C) with mural thrombi (A, arrows), ectasia (C) periarterial soft tissue (D, E; arrows), and stenosis (F, G; arrows). Panel C demonstrates ectasia of the entire coronary tree with focal fusiform aneurysmal dilatations (arrows).

Supporting image 3

Figure 3. Arteritis and periarteritis. A) Coronary computed tomography (CTA) in the short-axis view demonstrating the left anterior descending artery (LAD) aneurysm (arrow). B) Delayed contrast-enhanced CT showing enhancement of the aneurysmal LAD wall consistent with arteritis (arrow). C) LAD curved planar reformatted (CPR) and D) Pseudo colorized image of the LAD CPR image showing the soft tissue thickening around the LAD (arrows). E) Delayed phase image in short axis showing enhancement of the soft tissue thickening consistent with periarteritis (arrows).


Disclosures: G. Katz, None; s. hedgire, None; J. Stone, Cook Medical; S. Perez-Espina, None; A. Fernandes, None; C. Perugino, None; Z. Wallace, Sanofi, Bristol-Myers Squibb(BMS), Zenas Biopharma, Horizon, Shionogi; J. Stone, Horizon Theraputics, Sanofi, Amgen, Argenx, Bristol-Myers Squibb(BMS), Chemocentryx, Kyverna, Novartis, Palleon Pharmaceuticals, PPD, Q32, Star Therapeutics, Roche, Mirabio, Spruce Biosciences, Steritas, Zenas.

To cite this abstract in AMA style:

Katz G, hedgire s, Stone J, Perez-Espina S, Fernandes A, Perugino C, Wallace Z, Stone J. Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/coronary-arteritis-and-periarteritis-secondary-to-igg4-related-disease-in-a-large-single-center-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/coronary-arteritis-and-periarteritis-secondary-to-igg4-related-disease-in-a-large-single-center-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology